Media Thread, page-3376

If interested, put this event into your diary. LC will be presenting on Imugene at 11:10am.

When

Thu, Nov 4, 2021 · 9:00 AM Sydney (GMT 11:00)

Agenda

9am

The investment thesis

Expert investors unpack why, when and how to invest in ASX-listed biotechs. This discussion will help you understand potential risks and rewards through the clinical trial phase through commercialisation, the benefits of partnerships and M&A potential.

9:35am

Showcase: Immutep

Global leaders in immunotherapy drugs for cancer and autoimmune diseases, Immutep has four product candidates and is partnered with Novartis and GlaxoSmithKline.

10am

Showcase: Telix

Headquartered in Melbourne with operations in Europe, the US and Japan, Telix is developing a broad portfolio of diagnostic and therapeutic assets using nuclear medicine.

10:25am

Showcase: Opthea

With its lead product candidate in Phase 3 clinical trials, Opthea is developing novel therapies to treat highly prevalent and progressive retinal diseases.

10:50am

Showcase: Volpara

Volpara’s breast health software platform identifies early-stage breast cancer, with its breast density technology used in more than 39 countries.

11:10am

Showcase: Imugene

With three novel technology platforms, Imuegene aims to activate the immune system of cancer patients to identify and eradicate tumors.

11:30am

Valuation masterclass

Biotechnology companies vary greatly, and so do the methods and metrics used to value them. This whiteboard session will help you better understand how and why biotechs are valued as they are, and where to ascribe value going forward.

12pm

Close

Throughout the event you’ll be introduced to six ASX-listed biotechs making their mark. You’ll hear where they are on their path to commercialisation, and find out what they expect to achieve next. Agenda is subject to change